ChronoScale Holdings extended the Maturity of its $2.0 million outstanding term Loan to November 12, 2026. The amendment also permits the sale of Ekso Bionics, Inc. without treating it as a change of control, while requiring related liens on sold Collateral to be released automatically without payment to the lender.

Key Highlights

  • The amended agreement retains a maturity trigger tied to receipt of $2.4 million in net equity-sale proceeds.
  • A sale of Ekso Bionics, Inc. is defined as a Permitted Disposition and does not constitute a Change of Control.
  • Liens on Assets or Capital Stock sold in a Permitted Disposition are released automatically without payment to B. Riley Commercial Capital.

ChronoScale Holdings Corp (NASDAQ: CHRN) has extended the maturity of its $2.0 million outstanding term loan to November 12, 2026. The amendment also allows a sale of Ekso Bionics, Inc. to qualify as a Permitted Disposition, with related collateral releases built into the agreement.

Term Loan Amendment Extends Repayment Date

ChronoScale Intermediate, LLC, formerly Ekso Bionics Holdings, Inc. is the borrower, while Ekso Bionics, Inc. serves as guarantor. The amendment was entered into on September 12, 2026. Other material provisions remain unchanged, and the loan parties confirmed an outstanding principal balance of $2,000,000.

Sale Provisions Define Collateral Release

The amended agreement defines a Permitted Disposition as the sale of the guarantor through an asset sale, capital-stock sale, Merger or another structure. Such a transaction is excluded from the agreement’s definition of Change of Control. The borrower may submit UCC-3 termination statements on the lender’s behalf where permitted, while liens on other collateral continue securing the loan obligations.